Protocol T included 660 participants with centre-involving diabetic macular oedema and visual impairment. Participants were randomly assigned to treatment with aflibercept, bevacizumab or ranibizumab.<\/p>\n
After one year, average visual-acuity improvement across the full study population was 13.3 letters with aflibercept, 9.7 letters with bevacizumab and 11.2 letters with ranibizumab.<\/p>\n
The most important finding was that these differences were strongly influenced by vision at the beginning of treatment. When starting visual impairment was mild, average outcomes were similar between the three drugs. When starting vision was worse, aflibercept produced greater average improvement during the first year.<\/p>\n
For you as a patient, this means that Protocol T did not identify one universally superior injection for every person with DMO. Instead, it showed why baseline visual acuity and individual clinical circumstances matter when treatment is being selected.<\/p>\n
Which Treatments Were Compared?<\/h2>\n
![\"\"](\"https:\/\/www.eyecliniclondon.com\/blog\/wp-content\/uploads\/2026\/07\/imagess38.jpg\")
<\/p>\n
The DRCR.net Protocol T Study compared three widely used anti-VEGF medications for the treatment of diabetic macular oedema (DMO): aflibercept, bevacizumab, and ranibizumab. If you are diagnosed with DMO, your ophthalmologist may consider one of these treatments depending on your vision, retinal findings, and individual clinical circumstances.<\/p>\n
Each of these medications works by blocking vascular endothelial growth factor (VEGF), a protein that contributes to abnormal blood vessel leakage and retinal swelling. By reducing the effects of VEGF, these injections help decrease fluid accumulation in the macula and may help preserve or improve vision over time. Although all three medicines<\/p>\n
Although all three medicines share the same basic mechanism of action, researchers wanted to determine whether there were meaningful differences in their clinical performance. The Protocol T Study provided valuable evidence showing how each treatment performed in patients with different levels of vision loss, helping your ophthalmologist make more informed and personalised treatment decisions.<\/p>\n
Understanding Anti-VEGF Therapy<\/h2>\n
Anti-VEGF therapy is the standard treatment for many people with diabetic macular oedema (DMO). If you have DMO, these medicines work by blocking vascular endothelial growth factor (VEGF), a protein that increases blood vessel leakage inside the retina and contributes to swelling in the macula.<\/p>\n
By reducing leakage and controlling swelling in the macula, anti-VEGF injections may improve your vision or help prevent further deterioration. As the fluid within the retina decreases, the macula can function more effectively, allowing many patients to maintain or achieve better visual outcomes.<\/p>\n
Regular injections are often needed to maintain these benefits because the effects of anti-VEGF medicines gradually wear off over time. Your ophthalmologist will monitor your vision and retinal health during follow-up appointments and recommend an individualised treatment schedule to support long-term visual outcomes.<\/p>\n
The Main Findings<\/h2>\n
The DRCR.net Protocol T Study found that all three anti-VEGF medications improved vision in patients with diabetic macular oedema (DMO). If you have DMO, this means that each of the treatments studied was shown to be effective in reducing macular swelling and helping to preserve or improve vision.<\/p>\n
One of the most important discoveries was that the degree of visual improvement depended on how much vision patients had before starting treatment. People with better baseline vision often achieved similar outcomes with the different medications, whereas those with more severe vision loss experienced greater differences in treatment response. This demonstrated that the best choice of injection may vary from one patient to another.<\/p>\n
These findings helped support a more personalised approach to DMO treatment. Rather than recommending the same anti-VEGF medicine for every patient, your ophthalmologist can consider your visual acuity, retinal findings, and overall clinical condition to select the treatment that is most appropriate for you and your long-term visual outcomes.<\/p>\n
Patients with Better Starting Vision<\/h2>\n
The DRCR.net Protocol T Study found that among patients whose vision was only mildly affected before treatment, all three anti-VEGF medications produced broadly similar improvements. If you begin treatment for diabetic macular oedema (DMO) while your vision is still relatively good, you may achieve positive outcomes with more than one available treatment option.<\/p>\n
This finding suggested that several anti-VEGF therapies could effectively reduce macular swelling and help preserve or improve vision in patients with milder visual impairment. Because the visual outcomes were comparable, the choice of treatment did not necessarily depend on effectiveness alone.<\/p>\n
Instead, your ophthalmologist may also consider other important factors when recommending the most appropriate treatment for you. These may include your overall eye health, medical history, treatment schedule, cost and availability where relevant, and your individual response during follow-up. This personalised approach supports a treatment plan tailored to your specific needs while aiming to achieve the long-term visual outcomes.<\/p>\n
Patients with More Severe Vision Loss<\/h2>\n
The DRCR.net Protocol T Study found that patients who had poorer vision before starting treatment experienced different outcomes depending on the anti-VEGF medication used. If you have diabetic macular oedema (DMO) with more significant vision loss, the study showed that aflibercept produced greater visual improvement during the first year of treatment compared with the other medications that were evaluated.<\/p>\n
This important finding helped influence treatment selection for patients with greater baseline visual impairment for more advanced DMO. Rather than using the same injection for every patient, the results suggested that people with greater vision impairment may benefit from a treatment strategy that takes the severity of their condition into account.<\/p>\n
The study highlighted the value of tailoring treatment to disease severity. If you require anti-VEGF therapy, your ophthalmologist will consider your current visual acuity, retinal findings, and overall eye health before recommending the medication that is most appropriate for your individual circumstances and long-term visual outcomes.<\/p>\n
Importance of OCT Imaging<\/h2>\n
Optical coherence tomography (OCT) played an essential role throughout the DRCR.net Protocol T Study. If you have diabetic macular oedema (DMO), OCT allows your ophthalmologist to obtain detailed cross-sectional images of your retina and accurately measure the amount of swelling in the macula.<\/p>\n
During the study, clinicians used OCT to monitor how the retina responded to each anti-VEGF treatment over time. This imaging technology made it possible to assess changes in retinal thickness with great precision, helping researchers understand how effectively each medication reduced fluid accumulation and supported retinal health.<\/p>\n
Today, OCT remains a cornerstone of diabetic retinal care. If you are receiving treatment for DMO, your ophthalmologist will use OCT alongside vision assessments to diagnose your condition, monitor your response to treatment, and make informed decisions about your ongoing care. This combination of advanced imaging and personalised treatment supports informed treatment decisions and long-term visual outcomes<\/p>\n
Retinal Thickness Improvements<\/h2>\n
The DRCR.net Protocol T Study also evaluated changes in retinal thickness using optical coherence tomography (OCT), an imaging technique that provides detailed cross-sectional views of the retina. If you have diabetic macular oedema (DMO), OCT allows your ophthalmologist to measure the amount of swelling in your macula and monitor how well your treatment is working over time.<\/p>\n
The study found that all three anti-VEGF medications reduced retinal swelling, demonstrating that each treatment was effective at improving the underlying retinal changes associated with DMO. However, researchers also showed that improvements in retinal thickness did not always correspond exactly with the degree of visual improvement, making visual acuity an equally important factor when choosing treatment.<\/p>\n
By combining OCT imaging with regular vision assessments, your ophthalmologist can gain a more complete understanding of how your eyes are responding to treatment. This personalised approach helps ensure that your treatment plan is based on both structural improvements within your retina and the visual outcomes that matter most to you.<\/p>\n
Clinical Insight:<\/strong><\/p>\n An OCT scan is extremely important, but treatment decisions should not be based on retinal thickness alone. Some eyes can retain residual thickening while maintaining useful visual outcomes. Your ophthalmologist therefore considers your OCT appearance together with visual acuity, symptoms and the pattern of response over time.<\/p>\n In the DRCR.net Protocol T Study, anti-VEGF injections were given according to a structured treatment schedule with regular follow-up. The number of injections varied depending on how well each patient responded. Today, treatment frequency is still personalised according to vision, OCT findings, and retinal response.<\/p>\n Overall, DMO treatment frequency is not the same for every patient. Regular monitoring allows treatment schedules to be adjusted according to disease activity, treatment response and the regimen being used this personalised approach helps support the best possible visual and retinal outcomes over time.<\/p>\n The DRCR.net Protocol T Study continued beyond the initial treatment period to evaluate the long-term effectiveness of the three anti-VEGF medications. If you are receiving treatment for diabetic macular oedema (DMO), these longer follow-up data provide valuable information about how your vision and retinal health may change over time.<\/p>\n Researchers observed that, although there were important differences between the medications during the first year for some patients, these differences became smaller over time for many individuals receiving ongoing care.The findings highlighted the importance of continued monitoring and appropriate treatment after the initial treatment period in achieving good long-term visual outcomes.<\/p>\n Long-term follow-up remains an essential part of modern DMO management. If you are undergoing anti-VEGF therapy, your ophthalmologist will continue to monitor your vision, retinal thickness using optical coherence tomography (OCT), and overall treatment response. These regular reviews allow your treatment plan to be adjusted when necessary, helping you maintain the vision over the long term<\/p>\n Long-Term Evidence Note<\/strong><\/p>\n The randomised treatment phase of Protocol T lasted two years. A later extension study invited eligible participants to return for assessment five years after the original randomisation.<\/p>\n By the five-year visit, treatment during the previous three years had been managed through usual clinical care rather than the original randomised Protocol T treatment programme. This means that the five-year results provide useful information about long-term outcomes, but they should not be interpreted as a continuing randomised comparison of aflibercept, bevacizumab and ranibizumab.<\/p>\n Among participants who attended the five-year assessment, average visual acuity remained 7.4 letters better than it had been at the beginning of the original study. However, average vision had declined by 4.7 letters between years two and five.<\/p>\n For patients, the message is that early treatment can provide meaningful visual benefit, but DMO often requires long-term observation and continuing individualised care. The initial choice of medicine matters, particularly in some visual-acuity groups, but continued monitoring and appropriate retreatment are also essential.<\/p>\n Protocol T carefully monitored ocular and systemic adverse events across all three treatment groups. Overall safety findings were broadly reassuring, although individual medical history and cardiovascular risk remain relevant when anti-VEGF treatment is considered. Your ophthalmologist will assess the potential benefits and risks of treatment in the context of your eye condition and general health.<\/p>\n Throughout the trial, researchers carefully monitored participants for both eye-related and general health complications. They assessed not only how well the medications improved vision and reduced retinal swelling, but also whether any treatment-related side effects or adverse events occurred during the follow-up period. This comprehensive monitoring helped establish the overall safety of the therapies.<\/p>\n Safety remains an important consideration when selecting the most appropriate treatment for you. Your ophthalmologist will consider your eye condition, medical history, overall health, and individual risk factors before recommending an anti-VEGF medication, ensuring that your treatment plan balances both effectiveness and safety for the best possible long-term outcome.<\/p>\n The DRCR.net Protocol T Study strongly influenced treatment selection for diabetic macular oedema (DMO). If you are diagnosed with DMO today, your treatment plan is likely to be influenced by the evidence generated by this landmark clinical trial.<\/p>\n Rather than recommending the same anti-VEGF medication for every patient, ophthalmologists now consider factors such as your baseline visual acuity, the severity of your retinal swelling, your overall eye health, and your individual clinical circumstances before selecting the most appropriate treatment. This evidence-based approach allows therapy to be tailored to your specific needs instead of relying on a single treatment strategy for everyone.<\/p>\n This evidence has supported a more personalised approach to patient care by helping ophthalmologists match treatment to the characteristics of each individual. If you require treatment for diabetic macular oedema, your ophthalmologist will use the findings from Protocol T, together with your examination results and OCT scans, to recommend the anti-VEGF therapy that offers the treatment approach appropriate for your circumstances<\/p>\n UK Clinical Practice Note<\/strong><\/p>\n Current UK management of diabetic macular oedema is broader than the three-drug comparison tested in Protocol T.<\/p>\n NICE recommends discussing anti-VEGF treatment, macular laser treatment, steroid treatment and observation according to the type of DMO and the patient’s individual circumstances.<\/p>\n For centre-involving DMO with visual impairment and central retinal thickness of 400 micrometres or more, NICE recommends offering anti-VEGF treatment and discussing the advantages and disadvantages of the available options.<\/p>\n For centre-involving DMO with visual impairment and central retinal thickness below 400 micrometres, anti-VEGF treatment or macular laser treatment may be considered. For centre-involving DMO with good vision, defined by NICE as 79 letters or better, observation or macular laser treatment may be considered.<\/p>\n NICE NG242 notes that, when the guidance was published in August 2024, licensed anti-VEGF options for visual impairment due to DMO included aflibercept, ranibizumab, faricimab and brolucizumab. Bevacizumab was one of the Protocol T treatments, but its ocular use for DMO is off-label in the UK.<\/p>\n For you, this means that Protocol T remains influential, but modern treatment decisions also take account of current licensing, NICE recommendations, OCT findings, visual acuity and your previous treatment response.<\/p>\n Since the publication of the DRCR.net Protocol T Study, retinal medicine has continued to evolve. If you are being treated for diabetic macular oedema (DMO) today, you have access to a wider range of treatment options than were available when the study was first conducted.<\/p>\n New anti-VEGF agents, longer-lasting therapies, and intravitreal steroid implants have expanded the options available for managing DMO. These advances give your ophthalmologist greater flexibility to tailor treatment according to your individual needs, treatment response, and any other eye or medical conditions you may have. For some patients, newer therapies may also help reduce the frequency of injections while maintaining good control of retinal swelling.<\/p>\n Research continues to improve long-term outcomes for people with diabetic macular oedema. As new evidence becomes available, your ophthalmologist can recommend the most appropriate treatment strategy for you, combining the lessons learned from Protocol T with the latest advances in retinal care to help preserve your vision over the long term.<\/p>\n Treating diabetic macular oedema (DMO) involves much more than receiving anti-VEGF injections alone. If you have diabetes, the way you manage your overall health plays a major role in protecting your eyes and reducing the risk of further vision loss.<\/p>\n Blood glucose and blood pressure management are important parts of reducing wider diabetes-related risks, while cholesterol management forms part of broader diabetes and cardiovascular care. \u00a0Healthy lifestyle choices, such as eating a balanced diet, staying physically active, avoiding smoking, and attending regular diabetes reviews, also contribute to better long-term eye health. These measures work alongside your eye treatment rather than replacing it.<\/p>\n Overall diabetes management remains fundamental to preserving your vision. By working closely with both your ophthalmologist and your diabetes care team, you can help control the underlying condition while receiving appropriate treatment for DMO. This comprehensive approach supports the timely monitoring and management of your condition to maintain your vision and reduce the risk of future diabetic eye complications.<\/p>\nTreatment Frequency<\/h2>\n
\n
Long-Term Follow-Up<\/h2>\n
![\"\"](\"https:\/\/www.eyecliniclondon.com\/blog\/wp-content\/uploads\/2026\/07\/imagess37.jpg\")
<\/p>\nSafety Findings<\/h2>\n
Influence on Clinical Practice<\/h2>\n
Advances Since Protocol T<\/h2>\n
Importance of Diabetes Management<\/h2>\n
How Wider Diabetes Management Supports Eye Health<\/h2>\n
![\"\"](\"https:\/\/www.eyecliniclondon.com\/blog\/wp-content\/uploads\/2026\/05\/1-17.jpg\")
<\/p>\n